Skip to main content

Table 1 Clinical characteristics and CT features of 425 patients with GSTs in both training and validation

From: Convolutional neural network applied to preoperative venous-phase CT images predicts risk category in patients with gastric gastrointestinal stromal tumors

 

GSTt0 (n = 154)

GSTt1

(n = 84)

GSTt2

(n = 59)

P

GSTv0

(n = 67)

GSTv1

(n = 35)

GSTv2

(n = 26)

P

Pt&v

Sex (Male/Female)

78/76

38/46

31/28

.634a

38/29

16/19

18/8

.186a

.201a

Mean age(y)

60.85 ± 0.82

59.31 ± 1.50

58.85 ± 2.13

.399B

60.97 ± 1.61

62.77 ± 3.09

59.04 ± 4.16

.377B

.362b

Symptom

   

.075a

   

.191a

.642a

 0

51

36

16

 

24

14

6

  

 1

86

35

30

 

33

17

11

  

 2

17

13

13

 

10

4

9

  

Risk category

        

.980a

 0

154

   

67

    

 1

 

84

   

35

   

 2

  

59

   

26

  

Location*†

   

0.967

   

0.458

0.043

 Cardia

6

3

3

 

3

2

1

  

 Fundus

51

27

16

 

18

6

3

  

 Body

86

48

37

 

35

24

19

  

 Antrum

11

6

3

 

11

3

3

  

Contour*

   

<0.001

   

<0.001

0.726

 Round

66

14

1

 

35

3

1

  

 Oval

59

14

8

 

23

7

1

  

 Irregular

29

56

50

 

9

25

24

  

Growth pattern*

   

<0.001

   

<0.001

0.934

 Endophytic

77

25

8

 

34

9

2

  

 Exophytic

56

44

22

 

25

20

9

  

 Mixed

21

15

29

 

8

6

15

  

Necrosis*

49

65

51

<0.001

24

26

22

<0.001

0.779

Calcification

22

15

14

0.258

6

9

4

0.087

0.553

Surface ulceration*

14

24

38

<0.001

3

10

15

<0.001

0.937

LN*

4

5

10

0.002

0

2

4

0.005

0.492

Hemorrhage*

0

2

8

<0.001

0

0

2

0.018

0.721

Intratumoral vessel*

12

26

26

<0.001

10

10

16

<0.001

0.143

Peritumoral exudation*

0

2

9

<0.001

0

1

3

0.006

0.992

Necrosis under the tumor wall*

34

45

45

<0.001

14

20

17

<0.001

0.714

CTU (HU)

35.32 ± 0.35

35.79 ± 0.64

34.33 ± 0.92

0.499

34.66 ± 0.95

35.81 ± 1.81

34.25 ± 2.44

0.706

0.642

CTA (HU)

56.93 ± 1.64

59.63 ± 3.00

57.09 ± 4.28

0.430

57.74 ± 4.18

59.36 ± 8.00

56.53 ± 10.77

0.798

0.899

CTV (HU)

69.05 ± 1.81

73.32 ± 3.32

68.92 ± 4.73

0.134

71.55 ± 6.17

74.73 ± 11.81

71.26 ± 15.89

0.717

0.258

DEAP (HU)

21.61 ± 1.44

23.84 ± 2.63

22.76 ± 3.75

0.534

23.09 ± 4.08

23.55 ± 7.81

22.28 ± 10.51

0.956

0.718

DEPP (HU)

33.73 ± 1.87

37.53 ± 3.42

34.59 ± 4.87

0.249

36.90 ± 6.56

38.92 ± 12.56

37.01 ± 16.90

0.890

0.193

LD (mm)*

27.43 ± 4.37

52.29 ± 8.01

88.85 ± 11.41

<0.001

26.40 ± 9.19

55.00 ± 17.60

74.88 ± 23.69

<0.001

0.470

SD (mm)*

22.38 ± 2.03

40.71 ± 3.71

62.72 ± 5.29

<0.001

21.66 ± 4.20

45.63 ± 8.04

56.49 ± 10.82

<0.001

0.905

LD/SD*

1.24 ± 0.001

1.28 ± 0.001

1.44 ± 0.001

<0.001

1.24 ± 0.001

1.24 ± 0.002

1.29 ± 0.001

0.010

0.167

  1. Note.—Except where indicated, data are numbers of tumors. GST = Gastric stromal tumor. GSTt0/1/2 and /GSTv0/1/2 = training or validation data for risk 0/1/2 GS. y = years. M ± SD = mean ± standard deviation. Calculated with χ2 test (a), Analysis of variance (B) and independent sample T test (b). Symptom 0/1/2 = asymptomatic/symptoms without hematemesis, melena/ hematemesis and/or melena. Risk 0/1/2 = very-low and low/ intermediate/high risk groups. LN = Lymph node. CTU/CTA/CTV = the CT attenuation value of unenhanced /arterial/venous phase. DEAP/DEPP = CTA - CTU/ CTV - CTU. LD = long dimension. SD = short dimension. Analysis of variance (P) and independent sample T test (Pt&v)
  2. *There were significant differences on the same variable in both the training and validation groups
  3. *†There was significant difference on the same variable only validation group
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us